Full-Time

Head of Marketing

Noctrix Health

Noctrix Health

51-200 employees

Prescription wearable neuromodulation for RLS.

Compensation Overview

$240k/yr

+ Annual performance bonus

Pleasanton, CA, USA

In Person

Bachelor's, MBA

Category
Growth & Marketing (2)
,
Required Skills
Market Research
Forecasting
Branding/Brand Strategy
SEO
Data Analysis

Get referred to Noctrix Health

See people who can refer or advise you

Requirements
  • 10+ years of progressive marketing leadership experience, preferably within medical device, digital health, healthcare technology, consumer health, or wearable technology industries
  • Proven track record of building and scaling successful direct-to-consumer (DTC) growth engines and customer acquisition programs
  • Experience launching innovative products and building category-defining brands
  • Deep understanding of healthcare ecosystems, regulatory environments, clinical marketing, and reimbursement dynamics
  • Strong expertise in brand strategy, demand generation, performance marketing, product marketing, and customer lifecycle management
  • Experience managing significant marketing budgets and measuring performance against business objectives
  • Strong analytical mindset with experience leveraging data to drive marketing decisions and optimize performance
  • Experience with marketing technology platforms, CRM systems, marketing automation tools, and analytics solutions
  • Demonstrated success leading high-performing teams within fast-paced, growth-oriented environments
  • Exceptional communication, storytelling, executive presentation, and stakeholder management skills
  • Proven ability to influence and collaborate across executive leadership, product, clinical, commercial, and operational teams
  • Bachelor's degree required
Responsibilities
  • Define and evolve the company's brand strategy, positioning, messaging architecture, and category leadership narrative
  • Develop and execute integrated marketing strategies aligned with corporate, commercial, and product objectives
  • Lead all go-to-market planning and execution for product launches, including clinical, provider, and consumer-facing campaigns
  • Partner closely with Product Management, Sales, Clinical Affairs, and Commercial Operations to optimize market adoption and customer engagement
  • Drive customer acquisition and revenue growth through scalable omnichannel marketing programs
  • Oversee digital marketing, paid media, SEO/SEM, lifecycle marketing, CRM marketing, and customer retention initiatives
  • Develop and execute demand generation programs that increase awareness, engagement, lead generation, and conversion
  • Lead market research, customer segmentation, competitive analysis, pricing strategy, and demand forecasting initiatives
  • Build and optimize marketing technology infrastructure, analytics frameworks, automation platforms, and reporting capabilities
  • Establish KPIs, dashboards, and performance metrics to measure marketing effectiveness and return on investment
  • Lead public relations, corporate communications, thought leadership initiatives, and crisis communication strategies
  • Develop content strategies and campaigns that position Noctrix Health as a category-defining leader in neurological health and wearable therapeutics
  • Build, mentor, and lead a high-performing marketing organization across brand, growth, digital, communications, and product marketing functions
  • Manage external agencies, strategic partners, vendors, and consultants to maximize marketing effectiveness
  • Serve as a strategic advisor to the Executive Leadership Team on growth strategy, market opportunities, customer insights, and brand development
  • Collaborate cross-functionally to ensure message consistency and alignment across all customer touchpoints
  • Develop annual marketing plans, budgets, and resource allocation strategies that support business objectives
Desired Qualifications
  • MBA or other advanced degree preferred
  • Experience in medical devices, digital therapeutics, wearable technologies, or consumer healthcare products
  • Experience supporting both healthcare provider and direct-to-consumer commercialization strategies
  • Experience leading marketing organizations through rapid growth, product launches, and category creation efforts
  • Familiarity with reimbursement, patient access, and healthcare policy considerations

Noctrix Health makes prescription wearable therapy for Restless Legs Syndrome using the NTX100 Tonic Motor Activation System (Nidra). It uses leg bands to stimulate the peroneal nerves at night, producing gentle muscle activation that reduces RLS sensations and improves sleep. The device is prescribed through healthcare providers for adults with moderate-to-severe, medication-refractory RLS and is backed by FDA De Novo clearance in 2023 following a Breakthrough Device Designation and a multi-center trial. The goal is to establish wearable therapeutics as a standard non-drug treatment option to improve sleep for people with RLS.

Company Size

51-200

Company Stage

Acquired

Total Funding

$90.5M

Headquarters

Pleasanton, California

Founded

2018

Get referred to Noctrix Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Noctrix reported about $24 million annual run-rate revenue before closing, already commercializing.
  • CMS issued dedicated HCPCS codes and payment in 2024, reducing patient access friction.
  • ResMed can cross-sell Nidra through existing sleep clinics, HME partners, and international distribution.

What critics are saying

  • ResMed must integrate Noctrix by late 2026 while preserving sales momentum and reimbursement.
  • RLS prescriptions depend on sleep physicians and HMEs; coverage changes would choke adoption quickly.
  • If Nidra stalls below ResMed's expectations, the asset becomes a small, deprioritized portfolio experiment.

What makes Noctrix Health unique

  • Nidra is FDA De Novo-cleared, drug-free TOMAC for medication-refractory RLS.
  • AASM guidelines recognized peroneal nerve stimulation in 2024, validating Noctrix's mechanism.
  • ResMed completed the $340 million acquisition on June 1, 2026, giving channel reach.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

2%

2 year growth

0%
Sleep Review Magazine
May 5th, 2026
Resmed to expand sleep portfolio with $340M acquisition of restless legs syndrome device maker.

Resmed to expand sleep portfolio with $340M acquisition of restless legs syndrome device maker. Resmed will acquire the manufacturer of an fda-cleared nerve stimulation device for refractory RLS, a move that leverages its existing sleep physician and home medical equipment channels. Key takeaways: * Resmed has signed an agreement to acquire Noctrix Health, maker of the Nidra device, for a purchase price of $340 million. * The acquisition targets the estimated 7% of adults globally affected by RLS, a population with meaningful overlap with obstructive sleep apnea. * The transaction is expected to close around June 1, 2026, with revenue to be reported within Resmed's Americas Devices category. Resmed has signed a $340 million agreement to acquire Noctrix Health, a medical device company with an FDA de novo classified product indicated for the treatment of refractory moderate-to-severe restless legs syndrome (RLS). The flagship product, Nidra, is a noninvasive nerve stimulation device. The acquisition marks Resmed's expansion into adjacent sleep health markets, targeting what is considered the third-most-prevalent sleep disorder after obstructive sleep apnea (OSA) and insomnia. RLS affects approximately 7% of adults globally, including around 17 million people in the US, and has a meaningful overlap with OSA. "RLS treatments from Noctrix are noninvasive, clinically proven, and drug-free, just like our CPAP/APAP and bilevel therapies," said Michael Farrell, CEO and chairman of the board at Resmed, during the company's third-quarter earnings call. Resmed, which has been an investor in Noctrix since 2024, plans to leverage its established market access to scale the therapy. Prescriptions for the device are written predominantly by sleep physicians and flow through the same home medical equipment (HME) and durable medical equipment (DME) delivery channels where Resmed currently holds a leading market share. "The reach of our Resmed brand among sleep physicians and HME providers as well as our national and international distribution channel strength makes us the best owner of this scarce asset," Farrell said. The transaction is targeted to close on or around June 1, 2026. Noctrix currently has an annual run rate revenue of approximately $24 million, which Resmed notes is growing at a faster rate and operating at a higher gross margin than Resmed's core business. Once closed, Noctrix's financials will be reported within Resmed's Americas Devices category. The acquisition is expected to result in an approximate $0.02 reduction in non-GAAP earnings per share for the fourth quarter of fiscal year 2026 as Resmed continues to invest in research and development and sales and marketing for the new asset.

Simply Wall St
May 1st, 2026
ResMed names new CFO and acquires Noctrix Health to expand into neurology

ResMed has appointed Aaron Bloomer as chief financial officer, replacing retiring CFO Brett Sandercock, and agreed to acquire Noctrix Health, a medical device company specialising in restless leg syndrome treatments. The moves mark a strategic shift for ResMed, which is primarily known for sleep apnoea devices and related software. The Noctrix acquisition expands the company's portfolio into neurological conditions affecting sleep quality, broadening its clinical scope beyond traditional respiratory care. Investors will be watching how ResMed balances capital allocation between its core sleep apnoea business and new neurology-related devices. Integration risks around Noctrix, including regulatory and reimbursement hurdles, remain key factors to monitor. At $213.81, ResMed shares trade approximately 26% below the analyst target of $288.21.

Michael West Media
May 1st, 2026
Snoring leader buys restless leg syndrome device maker - Michael West

Sleep apnoea company Resmed has acquired a California firm that makes a device for patients with restless leg syndrome, the third-biggest sleep disorder.

FinSMEs
Sep 2nd, 2025
Noctrix Health Raises Up To $33.5M in Debt and Equity Funding

Noctrix Health raises up to $33.5M in debt and equity funding.

FinancialContent
Aug 29th, 2025
Noctrix Health Raises $33.5M for RLS Therapy

Noctrix Health has raised $33.5 million to accelerate the U.S. commercialization of its Nidra® TOMAC therapy for Restless Legs Syndrome (RLS). The funding includes contributions from Blue Venture Fund, Sandbox Clinical Ventures, and a debt facility from Bridge Bank. The company has also expanded its leadership team, appointing Ivan Lubogo as Chief Commercial Officer and promoting Jonathan Charlesworth, Ph.D., to Chief Scientific Officer. Mark Verratti joins the Board of Directors.